197 related articles for article (PubMed ID: 21128988)
1. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Wei KK; Zhang LR; Zhang Y; Hu XJ
J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
[TBL] [Abstract][Full Text] [Related]
2. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2004 Aug; 175(2):287-93. PubMed ID: 15262185
[TBL] [Abstract][Full Text] [Related]
3. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
[TBL] [Abstract][Full Text] [Related]
4. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2005 Jun; 180(2):407-15. PubMed ID: 15910869
[TBL] [Abstract][Full Text] [Related]
5. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
6. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
7. The association of cytochrome 7A1 and ATP-binding cassette G8 genotypes with type 2 diabetes among Jordanian patients.
Abed E; Jarrar Y; Alhawari H; Abdullah S; Zihlif M
Drug Metab Pers Ther; 2021 Nov; 37(2):149-154. PubMed ID: 34845882
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.
Fu ZD; Cui JY; Klaassen CD
J Lipid Res; 2014 Dec; 55(12):2576-86. PubMed ID: 25278499
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
10. How the cytochrome 7a1 (CYP7A1) and ATP-binding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital.
Abed E; Jarrar Y; Alhawari H; Abdullah S; Zihlif M
Int J Clin Pharmacol Ther; 2021 Feb; 59(2):99-108. PubMed ID: 33074092
[TBL] [Abstract][Full Text] [Related]
11. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Kajinami K; Brousseau ME; Nartsupha C; Ordovas JM; Schaefer EJ
J Lipid Res; 2004 Apr; 45(4):653-6. PubMed ID: 14703505
[TBL] [Abstract][Full Text] [Related]
12. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
13. The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis.
Li Q; Hong J; Wu J; Huang ZX; Li QJ; Yin RX; Lin QZ; Wang F
J Clin Lipidol; 2014; 8(6):618-629. PubMed ID: 25499945
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Kadam P; Ashavaid TF; Ponde CK; Rajani RM
J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
[TBL] [Abstract][Full Text] [Related]
15. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy.
Srivastava A; Garg N; Srivastava A; Srivastava K; Mittal B
Dis Markers; 2010; 28(5):307-13. PubMed ID: 20592455
[TBL] [Abstract][Full Text] [Related]
16. ABCG5 and ABCG8 gene polymorphisms in type 2 diabetes mellitus in the Turkish population.
Gok O; Karaali ZE; Acar L; Kilic U; Ergen A
Can J Diabetes; 2015 Oct; 39(5):405-10. PubMed ID: 26088706
[TBL] [Abstract][Full Text] [Related]
17. [Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui RZ
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2195-9. PubMed ID: 24169327
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls.
Caamaño JM; Pacheco A; Lanas F; Salazar LA
Clin Chem Lab Med; 2008; 46(11):1581-5. PubMed ID: 19012522
[TBL] [Abstract][Full Text] [Related]
19. An association of ABCG8: rs11887534 polymorphism and HDL-cholesterol response to statin treatment in the Polish population.
Sałacka A; Boroń A; Gorący I; Hornowska I; Safranow K; Ciechanowicz A
Pharmacol Rep; 2021 Dec; 73(6):1781-1786. PubMed ID: 34173968
[TBL] [Abstract][Full Text] [Related]
20. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
